Clinical Trials

Impression Healthcare undertaking three clinical trials in 2019 for the creation of three distinct products with clinical evidence.

Clinical Trial – Sleep Apnoea

About 1M people in Australia have symptomatic Obstructive Sleep Apnoea


  • A trial to examine the benefits of a Dronabinol variant for severe Obstructive Sleep Apnoea Syndrome (OSAS) compared to a placebo.
  • A recent study by Carley et al* demonstrated an improvement in the Apnoea-Hypopnea Index (AHI) Scoring by over 30% in patients given nocturnal dronabinol
  • Impression is developing its own unique formulation in conjunction with Swinburne University to potentially enhance results
  • Participants identified as having severe OSAS (AHI >40) will be treated with a nocturnal Dronabinol variant will have their AHI periodically re-measured
  • Sleep Apnoea is under-treated due to CPAP machine “non-compliance”. Treatment with a simple pill is considered highly desirable
  • Comparable companies involved in Sleep Apnoea product development and manufacture include Resmed, Somnomed and Oventus.

Clinical Trial – Concussion

Former AFL Player John Barnes is leading a planned class action against the AFL regarding its treatment of concussion during the game*


  • CBD is known to be a neuroprotective agent and prevents secondary neurological damage after concussion and traumatic brain Injury (TBI) through a variety of anti-inflammatory mechanisms
  • The World Anti-Doping Authority (WADA) and the Australian Sports Anti-Doping Authority (ASADA) have recently confirmed that THC-Free (Synthetic) CBD is not illegal for consumption by sportspeople
  • Participants identified as having had a head injury or concussion during an AFL or NRL football match will be commenced on twice-daily CBD oil and undertake brain MRIs and cognitive scoring during the treatment program
  • Concussion in sport has been well-publicised with long-term neurologically problems in high profile individuals being attributed to concussions received in professional sports.
  • This will be a unique study and one of the first of its kind expected to generate significant interest.


Clinical Trial – TMJ Dysfunction

Temporomandibular Joint Dysfunction is a common problem with poor treatment options


  • CBD is a potent suppressor of inflammatory processes but is also recognised to reduce muscular spasm, joint spasticity, TMJ joint pain and anxiety related bruxism symptoms
  • A trial to examine the benefits of CBD oil for reducing the severity of Temporomandibular Joint Dysfunction (TMJ), as compared to placebo
  • Severe TMJ Disorder is highly detrimental to patient quality of life, because the symptoms can be chronic and difficult to manage
  • Participants identified as having severe TMJ (Grade 3) will be commenced on twice-daily CBD oil and have their TMJ grading re-measured weekly
Impression Healthcare logo

Want The Latest From IHL?

Join our investor mailing list to be notified of announcements when they are made and sent all the latest investor materials as they are published. 

Thanks for signing up! We'll be in touch shortly.